• KOL
    • Vitro Activity
    • In Vitro Activity Of...
    • In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.: Influence Statistics

      Expert Impact

      Concepts for whichthey havehas direct influence:Vitro activity,Cefepime drug resistance,Bacteria gram,Antimicrobial agents,Inhibitory concentration,8 micrograms,Gram negative,Negative bacteria.

      Key People For Vitro Activity

      Top KOLs in the world
      #1
      Ronald N Jones
      united states latin america vitro activity
      #2
      Michael A Pfaller
      united states candida spp latin america
      #3
      Helio Silva Sader
      united states latin america vitro activity
      #4
      David Martin Livermore
      pseudomonas aeruginosa united kingdom escherichia coli
      #5
      Arthur L Barry
      interpretive criteria vitro activity susceptibility tests
      #6
      James A Karlowsky
      united states vitro activity canadian hospitals

      In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.

      Abstract

      The in vitro susceptibility of 406 clinical isolates to BMY-28142, a new semisynthetic cephem, was evaluated and compared with cefpimizole, HR 810, ceftazidime, cefotaxime, moxalactam, and cefoperazone in a broth microdilution assay. On a weight basis, the activity of BMY-28142 against Escherichia coli, Proteus species, and Klebsiella-Enterobacter-Serratia was superior to the other cephems. Against gentamicin-susceptible and -resistant Pseudomonas aeruginosa, BMY-28142 was more active than the other cephems, except ceftazidime and HR 810. A total of 74% of gram-negative and 56% of gram-positive isolates resistant to third-generation cephalosporins were susceptible to less than or equal to 8 micrograms of BMY-28142 per ml. Finally, for 83% of tested isolates, the bactericidal concentration of BMY-28142 was within one dilution of the inhibitory concentration.

      Sign-in to see all concepts, it's free!

       

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.